GlassScriptPhysician profile
Haidr Agha
NPI 1003048117
$1,804.83
in general payments reported to CMS, 2019-2025
19 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.47 · 2020: $148 · 2021: $236 · 2022: $246 · 2023: $308 · 2024: $480 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,058 · Education: $70.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,058.45 |
| Education | $70.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $271.49 | 2020-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $190.39 | 2020-2024 | Jynarque |
| Vantive US Healthcare LLC | $172.24 | 2025 | |
| Amgen INC. | $149.83 | 2019-2024 | Krystexxa |
| Glaxosmithkline, LLC. | $103.61 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.71 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $94.99 | 2021 | |
| Novartis Pharmaceuticals Corporation | $88.47 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $86.78 | 2023 | Ultomiris |
| Vifor Pharma, INC. | $83.28 | 2022-2024 | Veltassa |
| Lilly USA, LLC | $82.18 | 2023-2025 | Jardiance |
| Akebia Therapeutics INC | $69.24 | 2020-2023 | Auryxia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.79 | 2023-2025 | Jardiance |
| Ardelyx, INC. | $61.16 | 2024-2025 | Ibsrela |
| Travere Therapeutics, INC. | $57.28 | 2024-2025 | Filspari |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $39.38 | 2022 | |
| Calliditas Therapeutics US INC. | $32.53 | 2023-2024 | Tarpeyo |
| Fresenius USA Marketing, INC. | $31.96 | 2023-2024 | Velphoro |
| Novo Nordisk INC | $21.52 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haidr Agha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.